Is Fidaxomicin currently available in the country and the official channels?

Fidaxomicin is a new macrolide antibiotic mainly used to treat refractory or recurrent Clostridioides difficile infection (Clostridioides difficile infection, CDI). It achieves bactericidal effects by selectively inhibiting bacterial RNA polymerase and blocking bacterial protein synthesis. Compared with traditional vancomycin or metronidazole, fidaxomicin has less impact on intestinal flora and can reduce the recurrence rate of infection.

In the domestic market, fidaxomicin has not yet received marketing approval, so ordinary patients cannot purchase the drug directly through hospitals or pharmacies, and it is not included in the medical insurance system. Due to the lack of formal supply channels in China, if patients need to use fidaxomicin, they can only rely on overseas drug imports or participate in relevant clinical trials. However, these channels have certain legal and logistical restrictions, and regulations need to be strictly followed.

In overseas markets, the specification of fidaxomicin original drug is 192mg*100 tablets, and each box sells for about more than 10,000 US dollars, which is relatively high. There are currently no generic drugs on the market, which means that if patients purchase original drugs through overseas channels, the financial burden will be relatively large. At the same time, they need to pay attention to the transportation and storage conditions of the drugs to ensure efficacy and safety.

Generally speaking, fidaxomicin is not yet available for direct purchase in China, and formal channels mainly rely on overseas imports or clinical trials. When considering using it, patients should first consult with a professional doctor and obtain drugs through legal channels and avoid purchasing through informal channels to prevent counterfeit drugs or the risk of drug use. At the same time, if fidaxomicin is approved for marketing in China in the future, it will provide a safer and more convenient treatment option for patients with recurrent CDI.

Reference link:https://www.drugs.com